Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and cTACE in Advanced ICC
NCT02994251Phase 2Terminated
- Sponsor
- Yale University
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and mitomycin c in intrahepatic cholangiocarcinoma (ICC), sponsored by Yale University. Primary endpoint: Progression-free Survival at 12 months. Started Jun 2017; status: terminated.
02
Drugs
doxorubicinmitomycin c
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02994251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994251.